Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
340 studies found for:    Open Studies | "Sarcoma"
Show Display Options
Rank Status Study
21 Recruiting Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma
Conditions: Stage IIB Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: sorafenib tosylate;   Drug: epirubicin hydrochloride;   Drug: ifosfamide;   Radiation: external beam radiation therapy;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
22 Recruiting Dasatinib and Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumors or Other Sarcomas That Cannot Be Removed by Surgery or Are Metastatic
Conditions: Gastrointestinal Stromal Tumor;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: Dasatinib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
23 Recruiting Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
Conditions: Stage IIA Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Drug: Pazopanib Hydrochloride;   Drug: Doxorubicin Hydrochloride;   Drug: Ifosfamide;   Other: Placebo;   Procedure: Therapeutic Conventional Surgery;   Radiation: External Beam Radiation Therapy;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
24 Recruiting Cabozantinib-s-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
Conditions: Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Metastatic Osteosarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Osteosarcoma
Interventions: Drug: Cabozantinib S-malate;   Other: Laboratory Biomarker Analysis
25 Recruiting Study in Localized and Disseminated Ewing Sarcoma
Condition: Ewing's Sarcoma
Interventions: Drug: Zoledronic acid;   Drug: Busulfan;   Drug: Treosulfan
26 Unknown  Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
Conditions: Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions: Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Procedure: adjuvant therapy;   Procedure: conventional surgery;   Procedure: neoadjuvant therapy;   Radiation: radiation therapy
27 Recruiting Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Condition: Sarcoma
Interventions: Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
28 Unknown  Bevacizumab and Radiation Therapy for Sarcomas
Conditions: Soft Tissue Sarcoma;   Fibrous Histiocytoma;   Liposarcoma;   Leiomyosarcoma;   Fibrosarcoma;   Synovial Sarcoma
Interventions: Drug: Bevacizumab;   Procedure: Radiation Therapy
29 Recruiting Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
Conditions: Osteosarcoma;   Paget's Disease;   Ewing Sarcoma
Intervention: Other: DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI
30 Unknown  Sarcoma Database at KFSH&RC
Condition: Sarcoma Database
Intervention: Other: Database
31 Recruiting A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma
Condition: Synovial Sarcoma
Intervention: Biological: NY-ESO-1 T Cells
32 Recruiting Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
Condition: Ewing's Sarcoma
Interventions: Drug: Standard treatment (as per protocol ISG SSG III);   Drug: Intensified chemotherapy
33 Unknown  Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Condition: Kaposi´s Sarcoma
Intervention: Drug: Bevacizumab
34 Not yet recruiting A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas
Conditions: Soft Tissue Sarcoma;   Bone Sarcoma
Intervention: Drug: Pembrolizumab
35 Unknown  Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms, Hands, Legs, or Feet Treated on Clinial Trial CRUK-VORTEX
Condition: Sarcoma
Interventions: Genetic: microarray analysis;   Genetic: molecular diagnostic method;   Other: biologic sample preservation procedure
36 Recruiting Proton Radiation for the Treatment of Pediatric Bone and Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Conditions: Non-rhabdomyosarcoma Soft Tissue Sarcoma;   Bone Sarcoma
Intervention: Radiation: Proton Beam Radiation
37 Recruiting A Phase I Study to Examine the Toxicity of Allogeneic Stem Cell Transplantation for Relapsed or Therapy Refractory Ewing Sarcoma and Rhabdomyosarcoma
Conditions: Ewing Sarcoma;   Rhabdomyosarcoma
Intervention: Biological: allogeneic stem cell transplantation
38 Recruiting Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
Condition: Ewing's Sarcoma
Interventions: Drug: Chemotherapy;   Procedure: Surgery;   Radiation: Radiotherapy
39 Not yet recruiting Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Conditions: Sarcoma, Soft Tissue;   Soft Tissue Sarcoma
Intervention: Drug: Pazopanib
40 Recruiting Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Condition: Sarcoma, Alveolar Soft Part
Interventions: Drug: Cediranib;   Drug: Sunitinib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years